3:35 PM
 | 
Jul 03, 2014
 |  BC Extra  |  Company News

UCB, Dermira in Cimzia deal

UCB Group (Euronext:UCB) granted Dermira Inc. (Redwood City, Calif.) exclusive rights to develop Cimzia certolizumab pegol to treat psoriasis in the U.S., Canada and the EU and exclusive rights to commercialize the product in the U.S. and Canada. UCB will retain commercialization...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >